Week In Review: Henlius Signs $196 Million Deal For Two Oncology Bifunctional Sialidase Candidates
July 02, 2022 at 14:59 PM EDT
Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development and sales milestones.
